Abstract
Hypoxia in tumours
Most if not all solid tumours are at least partially hypoxic. This is due to limited amount of vasculature, leaky or otherwise poorly functional tumour vessels with chaotic architecture. These vessels may have good perfusion but at the same time flow-through where the blood does not reach many parts of the cancer tissue and cannot supply the intensely proliferating tumour tissue with sufficient oxygen [1] . Up to 50-60% of locally advanced tumours exhibit hypoxic or anoxic tissue areas that are heterogeneously distributed within the tumour mass. These areas are not static either, but the oxygenation varies temporarily. At a given timepoint tumour cells are exposed to an oxygen gradient decreasing gradually from efficient oxygenation to near anoxia, e.g. at perinecrotic areas (for a review see [2] ). [2, 3] [4, 5] ). Moreover, hypoxia affects cellmatrix anchorage, activates breakdown of tight cell-cell junctions, activates cell migration and invasion [6, 7] . These increase the potential of cell invasion making the cells more prone to initiate metastatic programs. Finally, hypoxia may enhance the expansion of tumour cells with diminished apoptotic potential [8] . Cells that activate these responses and generate a more aggressive phenotype may be further selected from the tumour cell population by the hypoxia-created genetic instability [9] . [11] ). Accordingly, over 50 years, hypoxia has been understood to negatively impact radiation therapy [12, 13] . At least partially this has been explained by the reduced formation of reactive oxygen species in hypoxia but other apoptosis resistance mechanisms are likely to be involved. Hypoxic cells are also more resistant to many chemotherapeutic agents. This may be due to diminished availability of the agents in poorly vascularized region, to induction of multidrug resistance in hypoxia [14] but also because some cytostatic prodrugs require oxygen for activation [10] . In keeping with these, hypoxia correlates with poor prognosis in several cancer types [15] . These include at least breast cancers, head and neck squamous cell carcinoma (HNSCC), lung cancer and colorectal cancers [16] [17] [18] .
Hypoxia is associated with restrained proliferation and differentiation, it impairs energy production and cell viability, arrests cell growth and induces cell death in normal cells (reviewed in

). However, in a subset of carcinoma cells hypoxia can also function as a selection pressure for more malignant phenotype as a number of survival responses are activated in the hypoxic cancer cells. These include the activation of anaerobic metabolism, growth factor signalling and neovascularization as well as cell cycle regulation, cell proliferation and protein catabolism that enable a subset of tumour cells to survive in poorly oxygenated conditions (reviewed in
It is a long-known fact that hypoxia causes resistance to cancer therapy, namely radiation therapy and also chemotherapy (reviewed in [10]). Already in the early 1900s it was demonstrated that cells irradiated under hypoxic or anoxic conditions are less sensitive to radiation as compared to cells irradiated in oxygenated conditions (for a review see
Overview of the oxygen-sensing mechanisms
To adequately respond to hypoxia, a rapidly responding machinery that can be tightly controlled over a wide range of lowered oxygen tension has evolved. The best-characterized molecular responses to hypoxia are mediated through the activation of gene transcription (reviewed in [15, 19] [26] [27] [28] [29] [30] . Three human HIF prolyl hydroxylases that can hydroxylate the prolyl residues of HIF-␣ have been characterized [31, 32] . The [19, 33] [20, 34] . The HIF target genes encode proteins that enable cells to survive the oxygen depletion (Fig. 1) . Tumour hypoxia and the HIF-system are intensely involved in the process of tumour progression, conferring growth advantage to tumour cells and to the development of a more malignant phenotype. The understanding as to how hypoxia operates at the molecular level has generated great optimism that specific therapeutics for the PHD-HIF system could be designed to overcome the hypoxia-induced chemo-and radiation resistance. 
The family of HIF hydroxylases
Currently the HIF hydroxylases are known to consist of three prolyl hydroxylases, the PHDs and one asparaginyl hydroxylase, FIH (factor inhibiting HIF). PHDs belong to an evolutionarily conserved superfamily of non-haem iron containing dioxygenases [31, 32] . The family comprises at least three prolyl hydroxylases, PHD-1, -2 and -3. PHD isoenzymes 1, 2 and 3 consist of 407, 426 and 239 amino acids, respectively [35] (Fig. 2 ). All PHDs demonstrate expression of several mRNA species due to alternative splicing or translation initiation with poorly understood function [36, 37] [35] . The hydroxylase domains at the C-termini are well conserved while the N-terminal parts are more divergent [32] . Given the high Km values of PHDs [36] , they respond fairly linearly to the wide range of physiological oxygen tension and thereby seem to be well suited as cellular oxygen sensors. Interestingly though, PHD2 and PHD3 have been shown to retain significant activity in hypoxic conditions [38] . All PHDs can hydroxylate HIF-␣ in vitro [31, 32, 36, 39] . However, PHD2 has been proposed to be the main regulator of HIF-1␣, as the RNA interference directed against it is sufficient to induce HIF-␣ subunits in normoxia, whereas silencing of PHD1 and PHD3 had no effect on the stability of HIF-1␣ in normoxia or upon re-oxygenation of cells briefly exposed to hypoxia [40] [32, 36, 41] [32, 36, 38] . PHD2 on the other hand has relatively more influence on HIF-1␣ than HIF-2␣, whereas PHD3 more efficiently regulates HIF-2␣ [38] . Noticeably [43, 44] . [36, 45, 46] . PHD1 mRNA is particularly abundant in the testis and placenta and is slightly less expressed in the brain, liver, heart and adipose tissue [45] [46] [47] [48] . PHD2 mRNA is widely expressed in most tissues and has a more uniform expression pattern. The expression seems particularly abundant in adipose tissue and heart. PHD3 mRNA is also expressed at low level in many tissues but is most abundant in the heart and placenta [45, 46, 48] and to a lesser extent in skeletal muscle and adipose tissue [45, 46, 48] . In cell culture conditions the PHD expression has mainly been studied using cancer-derived cell lines. In normoxic conditions PHD3 mRNA expression is below detection levels in most cell lines studied, while PHD2 is rather uniformly expressed. In cultured cells the protein levels of PHD2 and 3 seem to correlate well with the mRNA levels but the PHD1 protein levels were found to be lower than would be expected from the mRNA levels [38] . [49] . For FIH prominent staining is seen at least in testicular cells [49] . Suggesting an important function in the central nervous system, all PHDs have [39] . Immunohistochemical studies of normal human tissues showed similar subcellular localization for PHD2 and 3, but PHD1 was shown to be mostly cytoplasmic with only weak nuclear staining in a proportion of cells [49] . [50, 55] . Noticeably, in contrast to the overall expression, hypoxia does not influence the subcellular localization of PHDs [53, 125] . In line with the cell culture studies, FIH staining is reported to be mostly cytoplasmic in a wide range of epithelial cells. [56] .
Expression of PHDs in normal tissues
Heart ϩ ϩϩϩ ϩϩϩ N/A ϩϩ ϩϩ Skeletal muscle ϩ ϩϩϩ ϩϩ N/A ϩ N/A Liver ϩϩ ϩϩ/ϩϩϩ ϩϩ ϩ/Ϫ ϩ/Ϫ ϩ/Ϫ Kidney ϩ ϩϩ ϩ ϩϩ ϩϩ ϩϩ Lung ϩ ϩ ϩ ϩ Ϫ ϩ Pancreas N/A ϩϩ N/A ϩ ϩ/Ϫ ϩ/ϩϩ Testis ϩϩϩ ϩϩ ϩ ϩϩ ϩϩ ϩϩ Placenta ϩϩϩ N/A ϩϩϩ ϩϩ/Ϫ ϩϩ ϩϩϩ Adipose tissue ϩϩ ϩϩϩ N/A Ϫ Ϫ Ϫ Endothelium N/A N/A N/A Ϫ Ϫ/ϩϩ/ϩϩϩ Ϫ/ϩϩ
Besides mainly cytoplasmic localization, more recent studies demonstrate also nuclear localization for endogenous PHD2 at least in a subpopulation of cells. This has been detected for example in cancer samples of squamous carcinoma cells and pancreatic endocrine tumours (PET) but also in matching cultured cells
Regulation of PHDs
PHD2 and PHD3 expression levels have been shown by several laboratories to be up-regulated in hypoxia. In contrast, PHD1 levels remain stable regardless of the oxygen tension [32, 40, 45, 57, 58] , or may even be reduced under hypoxia [38, 59] [60] . PHD2 gene contains a functional HRE within the promoter 0.5 kb upstream of the translation start site and is a direct HIF target [61] . PHD3 gene has a functional HRE as well, located within an enhancer region of the first intron 12 kb downstream of the transcription initiation site [62] . PHD1 promoter on the other hand has been reported to contain binding site for ARNT/HIF-1␤ by which HIF-1␤ might regulate the hypoxic down-regulation of PHD1 [63] . PHD2 mRNA and protein levels have been proposed to be up-regulated also in an aryl hydrocarbon receptor dependent manner under normoxia [64] .
Besides hypoxia, several other microenvironmental factors, such as growth factors and hormones regulate PHD expression. PHD1 mRNA levels are known to be oestrogen inducible [38] . In fact, PHD1 was first cloned as an oestrogen-induced gene in a breast cancer cell line [65] [67] [68] [69] [70] [71] [72] . However, there are differences as to which intermediates are the most potent ones as well as to which dioxygenases are preferentially inactivated (Fig. 2) [73, 74] . In contrast, the hypoxic reduction in HIF accumulation that is observed with nitric oxide treatment, has generated more controversy [75] [76] [77] . It has been proposed that nitric oxide, by inhibiting the mitochondrial respiration chain, allows more oxygen to be available for the PHDs in the proximity of the mitochondria. This would result in enhanced PHD activity and HIF degradation [77] . The proposed mechanism however, has not been fully supported by other studies [78] .
Finally [81] . [65] and in in vitro studies PHD1 stimulated cell proliferation of breast cancer cells [65] . Likewise, the mouse PHD1 functioned as a growth stimulator in mouse embryo fibroblasts in response to DNA damage [59] . However, in contrast to the growth promoting functions, ectopic expression of PHD1 suppressed tumour growth in a xenograft tumour mouse model using HCT116 colon carcinoma cells [59] . [83] . PHD2 has also been shown to suppress hypoxia-induced endothelial precursor cell proliferation [84] . Accordingly, PHD2 suppresses the recruitment of endothelial precursor cells and thereby vasculogenesis [85] . [87] . Also in line with its [88] .
PHDs in cell growth and differentiation
Due to their function as inhibitors of HIF-1␣ stability, the PHDs have been proposed to function as tumour suppressors in different cancer types. However, recent studies on PHD expression and their outcome in cancer cells draw a much more complicated picture (Fig. 3). A line of data implicates that PHDs have an essential function in normal cell growth and proliferation. Drosophila PHD is essential for cell growth in fat bodies and wing imaginal discs [82]. PHD1 was cloned as an oestrogen inducible gene in a breast cancer cell line
Similar to PHD1, PHD2 has been implicated both as an activator and inhibitor of cell proliferation depending on the cell type. As expected, PHD2 has a critical role in suppressing excessive erythropoiesis that is demonstrated by erythrocytosis caused by a hydroxylase inactivating mutation in the PHD2 gene
Much of the functions of the PHDs are not easily explained solely by their function as inducers of HIF degradation. Also the above two studies implied hydroxylase-independent action either by PHD2's ability to bind and recruit binding partners to HIF-1␣, such as OS-9 and ING4, or through PHD2 activity on the NF-B pathway. Perhaps related to its function in vascular formation, PHD2 is reported to be required for normal growth and FGF-2 and PDGF-induced proliferation of human pulmonary artery smooth muscle cells as well [86]. Besides the reported cell growth activating functions of PHD2, other evidence implies PHD2 as a potential tumour suppressor. A recent animal model suggests that partial inactivation of PHD2 can activate endothelial cells to form better functioning tumour vessels
Fig. 3 Schematic model of the HIF hydroxylase function that occurs in HIF-dependent (A) or HIF-independent manner (B). (A) The activities of different PHD isoforms towards the two HIF-␣ isoforms are illustrated by the line thickness. Main HIF-dependent functions of PHDs on different tumour cell types are indicated. (B) Some of the activities of the hydroxylases on potential non-HIF hydroxylation targets and their function on different tumour cell types. X indicates non-characterized hydroxylase targets. possible tumour suppressor function, PHD2 has been reported to induce senescence in carcinoma cells of endometrial cancer
The rat SM-20, a PHD3 homologue, was identified as a growthfactor responsive gene in smooth muscle cells [89] and as a mitochondrial apoptotic factor in neuronal cells in normoxic conditions [90] . Accordingly, PHD3 was shown to be both necessary and sufficient for apoptosis of neuronal cells after withdrawal of neural growth factor [91] . The PHD3 mediated apoptosis required hydroxylation activity, which however, did not seem to be HIF-dependent [91] . In line with this, KIF1B␤ was demonstrated to be the downstream effector of PHD3 [92] . Knockout studies underline the importance of the PHD3-induced apoptosis in the proper development of several neural cell-derived organs [93] . [94] .
Also in a subset of normoxic carcinoma cells the forced PHD3 expression has been shown to lead to caspase-dependent apoptosis. Surprisingly, this associated with oxygen-dependent protein aggregation. Since the aggregates contain diverse proteasomal components this might be partially due to PHD3-induced malfunction of the proteasomal system in a condition where PHD3 expression is retained in normoxic or reoxygenated conditions in some cell types
PHDs have also been implicated to have functions in cellular differentiation. For example, PHD3 regulates skeletal muscle differentiation [95] as well as differentiation of sympathoadrenal organs apparently by activating appropriate apoptosis [93] . PHD2 is needed for myocardial development in the mouse [96] [97] . In PET all PHDs and FIH are expressed at weak or moderate levels [98] . Similarly, in breast cancers all PHDs and FIH are moderately or strongly expressed [49, 50, 99] . These include the two major forms of breast cancer, ductal and lobular carcinomas. Whether the hydroxylase expression associates either with HER2 amplification or with oestrogen or progesterone receptor expression is unclear. Given that PHD1 is known to be oestrogen-inducible [65] , it would be sensible to investigate any association between the [50, 98] . A recent study further suggests that the PHD2 nuclear translocation may associate with cancer therapy response. In line with the association between nuclear PHD2 expression and tumour aggressiveness, in HNSCC a low nuclear staining of PHD2 (Ͻ10% of PHD2 positive nuclei) in the primary tumour was found to associate with good radiation response [100] . These imply that the nuclear localization of PHD2 would be beneficial for carcinoma cell growth and somewhat contradicts to the supposed functions of PHD2 as a down-regulator of HIF expression. However, as mentioned, no clear association between HIF-1␣ and PHD2 was detected neither in HNSCC nor in prostate cancer [50, 97] .
Expression of PHDs in cancer
Immunohistochemical studies in human cancers have revealed mainly increased but variable staining of PHDs (Table 2). Simplistically one might expect PHD expression to correlate with HIF-␣ inversely in normoxic tumour regions or positively in hypoxic areas. This seems however, not to be true in many tumours studied so far. For example, prominent PHD2 expression has been detected in large tumour regions simultaneously with HIF-1␣. Also PHD3, whose expression is very low in most tissues and cultured cancer cells, shows strong expression in seemingly non-hypoxic tumours [97] (Jokilehto et al., unpublished). In prostate cancer all PHDs are expressed at least moderately. Here the PHD2 expression inversely correlated with HIF-2␣, but no correlation was seen between the other PHDs or HIF-1␣
Also the subcellular localizations of PHD1, -3 and FIH have shown association with tumour behaviour. Cytoplasmic FIH-1 has been shown to associate with tumour grade in invasive breast cancer [99] . Patients with tumours expressing only cytoplasmic FIH-1 had a significantly shorter survival compared with those with exclusive nuclear expression. In this study the cytoplasmic FIH-1 expression was also an independent prognostic factor for poor disease-free survival in breast cancer. In a set of rarer cancers, the PET, high nuclear PHD1 or PHD3 expression was associated with a poorer survival. In line with the breast cancer study, also cytoplasmic FIH was significantly higher in malignant PETs and in PETs with lymph node metastases [98] . Interestingly, in addition to the cancer cells, the stromal expression of FIH correlated not only with its higher nuclear expression but also with poorer disease-free survival [98] .
In [83] . A germline PHD2 mutation (H374R) was also found in a patient with erythrocytosis and recurrent paraganglioma [101] . In line with this, a partial interruption of the PHD2-HIF pathway has been experimentally observed to cause erythrocytosis by activating a set of genes such as erythropoietin. These data point to a possible tumour suppressor function for PHD2 at least in the erythroid cell lineage [102, 103] [104] .
Although PHD3 is overexpressed in several cancers, including carcinomas, the role of it has mainly been studied in neuronal cells. Before understanding the role of PHD3 in the oxygen sensing pathway, the murine homolog (SM-20) was described to activate neuronal apoptosis in stressed conditions [90] . Later studies have shown that the loss of PHD3 is associated with development of pheochromocytomas by failure in apoptosis [91] that is mediated by a kinesin KIF1B␤ [92] . What [115, 117] .
Although PHD2 has been linked to non-HIF signalling, to our knowledge PHD2 hydroxylation targets other than HIF-␣ have not been described. Since PHD2 is evolutionarily the most conserved isoform and the main regulator of HIF-␣, it is tempting to speculate that PHD2 is the most HIF-specific isoform, while the other hydroxylases have evolved stronger capacity to target non-HIF proteins as well. PHD3 has been reported to target ATF-4 transcription factor [121] and myogenin [95] 
